Int Urol Nephrol:De Ritis(天冬氨酸转氨酶/丙氨酸转氨酶)比率在预测局部前列腺癌病人病理结果和预后的意义

2017-06-03 AlexYang MedSci原创

最近,有研究人员评估了De Ritis(天冬氨酸转氨酶AST/丙氨酸转氨酶ALT)比率在局部前列腺癌中危险分层中是否有用进行了研究,并且假设了一个简单的生化免复发生存预测模型。研究总共包括了438名经历过根治性前列腺切除术的病人。并且,在手术前1-7天,,研究人员收集了血样中AST和ALT数据。另外,定义AST和ALT值增加为超过40或56IU/L。研究发现,AST和ALT平均值为18.5(16-

最近,有研究人员评估了De Ritis(天冬氨酸转氨酶AST/丙氨酸转氨酶ALT)比率在局部前列腺癌中危险分层中是否有用进行了研究,并且假设了一个简单的生化免复发生存预测模型。研究总共包括了438名经历过根治性前列腺切除术的病人。并且,在手术前1-7天,,研究人员收集了血样中AST和ALT数据。另外,定义AST和ALT值增加为超过40或56IU/L。

研究发现,AST和ALT平均值为18.5(16-22)和14(11-18)IU/L。总共有15名(3.4%)和9名(2.1%)病人表现为AST值和ALT值增加。平均的De Ritis比率为1.33(1.11-1.60),并且ROC曲线表明了预测生化复发最好的截断为1.325。另外,研究人员还发现了更高的De Ritis比率与较大的年龄(p<0.001)、更高的肿瘤阶段(p<0.001)、格林森得分(p<0.001)、开创性入侵表现(p<0.001)、阳性手术切缘(p<0.001)和淋巴结转移(p=0.003)有关。多变量逻辑回归确认了De Ritis比率为最终格林森得分的一个独立预测因子(p<0.001),并且,多变量Cox回归表明了De Ritis比率可以作为BCRFS的一个独立的风险因子。另外,一个简单的包含De Ritis比率、病理肿瘤阶段和最终格林森得分的预测模型也许可以帮助BCRFS的风险分层。最后,研究人员指出,更高的De Ritis比率能够预测局部前列腺癌病人较差的病理结果和更高的BCR。一个包含De Ritis比率、病理肿瘤阶段和最终格林森得分的预测模型能够帮助BCRFS的风险分层

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046232, encodeId=fc362046232d0, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 29 14:31:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752042, encodeId=cce61e5204216, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Sat Oct 14 07:31:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395456, encodeId=7b9113954568c, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405725, encodeId=943f1405e2535, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046232, encodeId=fc362046232d0, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 29 14:31:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752042, encodeId=cce61e5204216, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Sat Oct 14 07:31:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395456, encodeId=7b9113954568c, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405725, encodeId=943f1405e2535, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046232, encodeId=fc362046232d0, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 29 14:31:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752042, encodeId=cce61e5204216, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Sat Oct 14 07:31:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395456, encodeId=7b9113954568c, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405725, encodeId=943f1405e2535, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046232, encodeId=fc362046232d0, content=<a href='/topic/show?id=80714e595e5' target=_blank style='color:#2F92EE;'>#局部前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47595, encryptionId=80714e595e5, topicName=局部前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e12a151, createdName=yangeasy, createdTime=Sun Oct 29 14:31:00 CST 2017, time=2017-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1752042, encodeId=cce61e5204216, content=<a href='/topic/show?id=a6cf209129b' target=_blank style='color:#2F92EE;'>#丙氨酸转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20912, encryptionId=a6cf209129b, topicName=丙氨酸转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88f36427533, createdName=aliceclz, createdTime=Sat Oct 14 07:31:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395456, encodeId=7b9113954568c, content=<a href='/topic/show?id=252d93386f8' target=_blank style='color:#2F92EE;'>#转氨酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93386, encryptionId=252d93386f8, topicName=转氨酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1405725, encodeId=943f1405e2535, content=<a href='/topic/show?id=a5404e589d7' target=_blank style='color:#2F92EE;'>#局部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47589, encryptionId=a5404e589d7, topicName=局部)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d14c2562456, createdName=chg122, createdTime=Mon Jun 05 06:31:00 CST 2017, time=2017-06-05, status=1, ipAttribution=)]
    2017-06-05 chg122

相关资讯

Biomed Pharmacother:葡萄籽来源的多酚对镉诱导的前列腺功能缺陷潜在的益处

葡萄被人们当作水果消费或者制成酒类饮品。最近,有研究人员通过为期20周的饮水方式,对小鼠模型口服60mg/L的CdCl2来诱导产生前列腺功能缺陷。并且,研究人员同样对小鼠进行为期20周的葡萄籽来源的多酚(GSP)口服试验。最后,研究人员通过多免疫组化和qPCR分析对前列腺的钙黏蛋白、纤连蛋白和平滑肌动蛋白的水平进行了测量。另外,研究人员通过检测丙二醛、一氧化氮、还原型谷胱甘肽/氧化型谷胱甘肽和酶促

Sci Rep:淋巴结转移的淋巴结外软组织转移可以影响前列腺癌复发

淋巴结转移中的外软组织转移通过淋巴结囊进入淋巴结脂肪组织,从而参与了肿瘤细胞的扩张。最近,这个形态特性表明可以作为各种癌症类型的重要预后因子,但是它在前列腺癌中的角色仍旧不清楚。最近,有研究人员鉴定了其在前列腺癌中的角色,并首次进行了前列腺组织的元分析,并与外科手术治疗的预后参数、淋巴结阳性前列腺病人包括ENE+和ENE-进行了比较。研究人员利用风险比(RRs)来总结死亡或者复发数,并利用危险比(

Sci Rep: 前列腺癌诊断中,横波弹性成像的准确性

许多研究已经建立了横波弹性成像(SWE)技术前列腺检测的高度诊断准确性,然而,它的应用仍旧存在争议。最近,有研究人员探究了前列腺癌诊断中横波弹性成像的准确性。研究人员利用元分析鉴定了PCa检测中,SWE技术的总的准确性,并且搜寻了PubMed(文献服务检索系统), Embase(荷兰医学文摘), Cochrane Library(考克兰图书馆), Web of Science(科学网) 和 CNK

Cancer Sci:雄激素抵抗性前列腺癌中细胞分裂相关1(CDCA1)肽接种疫苗**阶段临床试验

最近,研究人员筛选了细胞分裂相关1(CDCA1),并且作为致癌基因在几种癌症,包括前列腺癌中超表达。研究人员同样鉴定了一个高度免疫的HLA-A*2402限制性表位多肽,并且与CDCA1蛋白的部分一致。另外,利用CDCA1肽接种疫苗,对患有雄激素抵抗性前列腺癌(CRPC)的病人进行了第一阶段的临床试验。研究包括了多烯紫杉醇化疗失败的具有HLA-A*2402的12名CRPC病人,并让他们接受带有Mon

Sci Rep:Y-box结合蛋白(YB-1)的上调和核转运与ERG阴性前列腺癌不良预后有关

Y-box蛋白(YB-1)是一个RNA和DNA结合因子并且可以作为潜在的癌症预后因子。最近,研究人员为了评估YB-1的临床影响,在11152名前列腺癌病例中利用免疫组化技术进行了组织微阵列分析,并对细胞质和细胞核染色进行了分开的研究。研究发现,在正常上皮细胞中,细胞质YB-1没有或者很少,而在86.3%肿瘤细胞中发现。在肿瘤中,细胞质染色弱的、中等的和强的分别占29.6%、43.7%和13.0%,

SCI REP:前列腺癌根治术后盆底重建改选什么方法?

由此可见,接受根治性前列腺切除术的患者并且采用后路重建治疗尿失禁出现最少。采用前壁悬吊、前路重建联合后路重建治疗和前壁悬吊联合后路重建治疗在术后没有观察到明显的益处。